Third-party allogeneic mesenchymal stromal cells prevent rejection in a pre-sensitized high-risk model of corneal transplantation
Ryan, Aideen E.
Griffin, Matthew D.
MetadataShow full item record
This item's downloads: 215 (view details)
Cited 22 times in Scopus (view citations)
Lohan, Paul, Murphy, Nick, Treacy, Oliver, Lynch, Kevin, Morcos, Maurice, Chen, Bingling, Ryan, Aideen E. , Griffin, Matthew D., Ritter, Thomas. (2018). Third-Party Allogeneic Mesenchymal Stromal Cells Prevent Rejection in a Pre-sensitized High-Risk Model of Corneal Transplantation. Frontiers in Immunology, 9(2666). doi: 10.3389/fimmu.2018.02666
High-risk cornea transplant recipients represent a patient population with significant un-met medical need for more effective therapies to prevent immunological graft rejection due to heightened anti-donor immune response. In this study, a rat model of pre-existing anti-donor immunity was developed in which comeal allografts were rejected earlier than in non-pre-sensitized recipients. In this model, third-party (non-donor, non-recipient strain) allogeneic mesenchymal stromal cells (allo-MSC) were administered intravenously 7 and 1 days prior to transplantation. Rejection-free graft survival to 30 days post-transplant improved from 0 to 63.6% in MSC-treated compared to vehicle-treated control animals (p =